Evaluation of Prescribing Medications for Terminal Cancer Patients near Death: Essential or Futile
7
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose The purpose of this study is to evaluate the prescription of essential or futile medications for terminal cancer patients during their final admission. Materials and Methods We conducted a retrospective review of the medical charts of terminally ill cancer patients admitted to the Hemato-oncology Department of two teaching hospitals from March 1, 2007 to December 31, 2009. Essential medications were based on the drugs listed by the International Association for Hospice and Palliative Care, while futile medications were defined when short-term benefit to patients with respect to survival, quality of life, or symptom control was not anticipated. Results A total of 196 patients were included. Among essential medications, strong opioids were the most frequently prescribed drugs during the last admission (62.2% fentanyl,44.3% morphine), followed by megestrol (46.0%), and metoclopramide (37.2%); 51%of gastric protectors were prescribed with potential futility. Anti-hypertensive and antiglycemic agents were administered to those who experienced arterial blood pressure below 90 mm Hg (47.3%) or presented with a single measurement of fasting glucose below 50 mg/dL (10.7%), respectively. Statins were prescribed to 6.1% (12/196) of patients, and 75% of those prescriptions were regarded as futile. Conclusion Our data suggest that effective prescription of essential medications and withdrawal from futile medications should be actively reconciled for improvement of a patient’s end-of-life care.
Abstract
Purpose The purpose of this study is to evaluate the prescription of essential or futile medications for terminal cancer patients during their final admission. Materials and Methods We conducted a retrospective review of the medical charts of terminally ill cancer patients admitted to the Hemato-oncology Department of two teaching hospitals from March 1, 2007 to December 31, 2009. Essential medications were based on the drugs listed by the International Association for Hospice and Palliative Care, while futile medications were defined when short-term benefit to patients with respect to survival, quality of life, or symptom control was not anticipated. Results A total of 196 patients were included. Among essential medications, strong opioids were the most frequently prescribed drugs during the last admission (62.2% fentanyl,44.3% morphine), followed by megestrol (46.0%), and metoclopramide (37.2%); 51%of gastric protectors were prescribed with potential futility. Anti-hypertensive and antiglycemic agents were administered to those who experienced arterial blood pressure below 90 mm Hg (47.3%) or presented with a single measurement of fasting glucose below 50 mg/dL (10.7%), respectively. Statins were prescribed to 6.1% (12/196) of patients, and 75% of those prescriptions were regarded as futile. Conclusion Our data suggest that effective prescription of essential medications and withdrawal from futile medications should be actively reconciled for improvement of a patient’s end-of-life care.
참고문헌 (21)
- Fan G, "Symptom clusters in cancer patients: a review of the literature", Curr Oncol, 14, pp.173~179 (2007)
- Kirkova J, "Cancer symptom clusters: old concept but new data", Am J Hosp Palliat Care, 27, pp.282~288 (2010)
- Jimenez A, "Symptom clusters in advanced cancer", J Pain Symptom Manage, 42, pp.24~31 (2011)
- World Health Organization, "Cancer pain relief: with a guide to opioids availability", ~ (1996)
- De Lima L, "International Association for Hospice and Palliative Care list of essential medicines for palliative care", Ann Oncol, 18, pp.395~399 (2007)
- Lindqvist O, "Four essential drugs needed for quality care of the dying: a Delphi-study based international expert consensus opinion", J Palliat Med, 16, pp.38~43 (2013)
- Riechelmann RP, "Futile medication use in terminally ill cancer patients", Support Care Cancer, 17, pp.745~748 (2009)
- Fede A, "SPUse of unnecessary medications by patients with advanced cancer: cross-sectional survey", Support Care Cancer, 19, pp.1313~1318 (2011)
- Bayliss EA, "Statin prescribing patterns in a cohort of cancer patients with poor prognosis", J Palliat Med, 16, pp.412~418 (2013)
- Pud D, "The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes", J Pain Symptom Manage, 35, pp.162~170 (2008)
- Teunissen SC, "Prognostic significance of symptoms of hospitalised advanced cancer patients", Eur J Cancer, 42, pp.2510~2516 (2006)
- Narducci F, "Symptom improvement as prognostic factor for survival in cancer patients undergoing palliative care: a pilot study", Support Care Cancer, 20, pp.1221~1226 (2012)
- Curtis EB, "Prescribing practices of a palliative care service", J Pain Symptom Manage, 8, pp.312~316 (1993)
- Riechelmann RP, "Symptom and medication profiles among cancer patients attending a palliative care clinic", Support Care Cancer, 15, pp.1407~1412 (2007)
- Currow DC, "Prescribing in palliative care as death approaches", J Am Geriatr Soc, 55, pp.590~595 (2007)
- Lichter I, "The last 48 hours of life", J Palliat Care, 6, pp.7~15 (1990)
- 이순남, "말기 암환자의 임종 전 48시간 동안의 임상증상", 한국호스피스완화의료학회지, 10(4), pp.190~194 (2007), 한국호스피스완화의료학회
- 고수진, "임종 전 말기 암 환자의 임상 증상 및 징후의 변화", 한국호스피스완화의료학회지, 11(2), pp.99~105 (2008), 한국호스피스완화의료학회
- Radha Krishna LK, "The use of midazolam and haloperidol in cancer patients at the end of life", Singapore Med J, 53, pp.62~66 (2012)
- Jecker NS, "Medical futility. Who decides", Arch Intern Med, 152, pp.1140~1144 (1992)
- Vollrath AM, "Discontinuing cardiovascular medications at the end of life: lipid-lowering agents", J Palliat Med, 8, pp.876~881 (2005)